Is Bristol-Myers Squibb Company (BMY) overvalued or undervalued?

At a recent price of $67.66, Bristol-Myers Squibb Company (BMY) trades 110% below TickerWorth's blended fair value of $142.07 per share — a discounted-cash-flow model cross-checked against peer multiples and asset value — meaning the market currently prices BMY undervalued vs our estimate of what the business is intrinsically worth. Our fair value sits above the market, an implied +110.0% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.

One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values BMY at about $92.16 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.

The valuation discounts Bristol-Myers Squibb Company's projected free cash flows at a weighted-average cost of capital (WACC) of 6.3%, with a long-run terminal growth rate of 2.5%. About 84% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.

Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly -1.0% annual revenue growth for BMY. Our base case instead assumes about 4.9% average growth over the forecast, so the market is pricing in slower growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.

Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, BMY's modeled DCF value ranges from about $50.73 to $294.91 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.

How to read this page: the DCF fair value is what Bristol-Myers Squibb Company would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of BMY's intrinsic value. Figures update as new filings and prices come in.